Institute for Digestive Diseases
Institute for Digestive Diseases
Bozinovski S.Z.,Serbian Institute of Physiology |
Bozinovski S.Z.,University of Belgrade |
Krstic S.,Institute for Digestive Diseases |
Krstic S.,University of Belgrade |
And 4 more authors.
Clinical Laboratory | Year: 2014
Background: Vascular endothelial growth factor (VEGF) is a glycoprotein which exerts mitogenic effects on endothelial cells, enhances neoangiogenesis and microvascular permeability, influences leukocyte kinetics when upreg-ulated by hypoxia and high-glucose concentration in experimental conditions and in human pathology. Peritoneal synthesis of VEGF has been demonstrated in patients on peritoneal dialysis (PD) treated with glucose-based dialy-sate solutions.Methods: The aim of the study was to determine the serum and peritoneal effluent VEGF concentrations in patients on chronic PD and to assess the relationship between age, gender, comorbidities, dialysis modality and vintage, therapy with erythropoiesis stimulating agents (ESA), angiotensin-converting enzyme inhibitors (ACEi) and statins and VEGF concentrations. Data on the use of ACEi, ESA, and statins were collected from patients' medical histories. VEGF was measured in serum and peritoneal effluent using the quantitative sandwich enzyme immunoassay (ELISA) kits (Quantikine® Human VEGF, R&D Systems, USA & Canada). Complete blood count and standard biochemical analyses (serum glucose, urea, creatinine, total protein, albumin, cholesterol, triglycerides, sodium, potassium, chloride, iron, total iron-binding capacity, ferritin, fibrinogen, C-reactive protein, and intact parathyroid hormone) were performed in fasting venous blood samples. Dialysis and residual components of Kt/V and normalized weekly creatinine clearance were calculated based on 24-hour urine and effluent collections. Peritoneal transport type was determined using the peritoneal equilibration test.Results: Samples from 63 PD patients (39 males and 24 females, average age 61.97 ± 11.01 years) were analyzed. The average serum and effluent VEGF concentrations (231.84 ± 173.91pg/mL and 38.39 ± 49.38pg/mL, respectively) correlated significantly (p = 0.002). No significant difference was found in serum and effluent VEGF concentrations in relation to demographic characteristics, comorbidities, dialysis modality, therapy with ESA, ACEi, and statins. Patients treated with PD longer than 5 years had significantly higher serum VEGF levels (p < 0.05). Correlation analysis showed a statistically significant relationship between statin therapy and lower effluent VEGF concentration (p = 0.030). Serum VEGF concentration significantly correlated with fibrinogen serum concentration (p = 0.034) and glycemia (p = 0.004). Effluent VEGF concentration significantly correlated with cholesterolemia (p = 0.004).Conclusions: Serum VEGF concentrations were significantly higher in long term PD patients, and peritoneal effluent VEGF concentrations were significantly lower in patients receiving statins, suggesting a protective effect of those drugs on peritoneal membrane.
Trbojevic-Stankovic J.,Clinical Center Dr Dragisa Misovic Dedinje |
Obradovic M.,University of Belgrade |
Trpinac D.,University of Belgrade |
Lausevic Z.,Institute for Digestive Diseases |
Stojimirovic B.,Institute of Urology
Vojnosanitetski Pregled | Year: 2011
Background/Aim. During peritoneal dialysis (PD) an exchange of substances between blood and dialysate takes place through specific histological structures of peritoneum. Peritoneal double-layered serous membrane has, so far, mostly been studied with electron microscopy on experimental animals. The aim of this study was to assess integrity of peritoneal tissue in end-stage renal disease (ESRD) and PD patients using standard light microscopy and immunohistochemical methods. Methods. Peritoneal tissue biopsies were performed on 25 persons: 8 healthy donors during nephrectomy, 9 ESRD patients upon insertion of PD catheter, and 8 PD patients upon removal of the catheter for medical indications. The samples were fixed and prepared routinely for immunocytochemical staining by standardized streptavidin biotin AEC method using a LSAB2 ® HRP kit (Dako ®, Denmark) for collagen IV and analyzed by light microscopy. Results. We observed mesothelial detachment from lamina propria, duplicated basement membrane and much thicker blood vessel walls in ESRD and PD patients, compared to healthy subjects. Differences in histological structure, emphasized with immunostaining, indicated pathological alterations of peritoneal tissue in the renal patients. Conclusions. Imu-nohistochemistry can be used in studying histological alterations of peritoneal tissue in ESRD and PD patients. This method may indicate possible problems in filtration and secretion processes in this tissue.
News Article | November 3, 2016
FAIRPORT, NY, November 03, 2016-- William Y. Chey, MD, DSc, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.With more than 50 years of experience as a physician, educator and research scientist in gastrointestinal medicine, Dr. Chey is widely recognized for his expertise in the field of gastroenterology and hepatology. Prior to his retirement in 2000, he served as a professor of medicine and director of the Division of Gastroenterology and Hepatology at the University of Rochester Medical Center, and as a consultant gastroenterologist at Canandaigua VA Medical Center. He is a fellow of the American College of Gastroenterology and the American Gastroenterological Association, a member of the AGA Legacy Society, and was a member of the American Association for the Advancement of Science and American Physiological Society, among other medical organizations. In addition, he is the former president of the American Pancreatic Association and the American Society of Acupuncture. He was invited nationally and internationally as a visiting professor by numerous prestigious institutions in the United States, Europe, Asia and Mid-Eastern countries. In particular, he holds the titles of Honorary Professor at the Catholic University College of Medicine, Seoul, Korea and Visiting Professor at Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China and Korea University College of Medicine, Seoul, Korea.After completing his medical education in 1953 through the two top medical schools in Seoul, Korea, Seoul National University and Yonsei University in Seoul, Korea, and serving as a medical officer of the Republic of Korea in the Korean War, Dr. Chey emigrated to the United States in 1954 and had his post-graduate training including internship and residency in internal medicine at City Hospital of New York, fellowship in pathology at Mount Sinai Hospital, New York, and fellowship in hepatology at Jersey City Medical Center, Seton Hall University School of Medicine and Dentistry, Jersey City, NJ. Then he received advanced degrees of Master of Science in Gastroenterology in 1962 and Doctor of Science in Medicine in 1966 from the University of Pennsylvania School of Medicine. At Temple University Medical Center and the Samuel S. Fel's Research Institute, Temple University School of Medicine, Philadelphia, PA, he finished a fellowship in gastroenterology and became a faculty member in 1963. He was an Associate Professor of Medicine and Head of Gastrointestinal Research in 1971 when he was recruited by the University of Rochester School of Medicine and Dentistry, Rochester, NY. He was the Founding Director of the Isaac Gordon Center for Digestive Diseases and Nutrition at the Genesee Hospital and Attending Physician at Strong Memorial Hospital, Rochester, NY. In 1992, he became Director of the Division of Gastroenterology and Hepatology at the University of Rochester Medical Center. He was also the Founding Director of the William and Sheila Konar Center for Digestive and Liver Diseases at Strong Memorial Hospital until his retirement in 2000. During his tenure, he trained numerous clinical and research fellows from the United States and abroad, including Asia, Europe, South America, Mid-East and Africa. The majority of them returned to their native countries and are active in their leadership positions. During the following ten years, he enjoyed practicing gastrointestinal medicine at the Rochester Institute for Digestive Diseases and Sciences and was also actively involved in the American Gastroenterological Association and the American Pancreatic Association. He has been married to Fan K. Tang since 1959. They have 4 children; William D. married to Janine Zwiren, Donna married to Dale Hoellrich, Richard married to Maura Bauman, and Laura married to Richard Warren, and 9 grandchildren; Cameron, Brandon (deceased), Samuel, Megen, Russell, Paris, Wyatt, Josephine and LiLi.He contributed numerous articles to competitive scientific journals, and published many chapters in text-books and two books of his specialty and research. He was a member of the editorial board of the Pancreas and American Journal of Physiology, and has been the Editor-In-Chief of Clinical Endoscopy since 2011. He served as an active member of the National Institute of Health, Surgery and Bioengineering Study Section and a consultant to the Gastrointestinal Drug Advisory Committee, Food and Drug Administration, Department of Health and Human Services.In recognition of his contributions to medicine, Dr. Chey received a wide variety of honors and awards. He was the recipient of the V.L. William and Frisca Go Award for Life Time Achievement from the American Pancreatic Association, the Governor's Award for Excellence in Clinical Research from the American College of Gastroenterology, Distinguished Clinician Award and Mentor's Research Scholar Award from the American Gastroenterological Association, Distinguished Service Award from the Rochester Academy of Medicine and American Top Physicians Award in 2008 from the Consumers' Research Council of America. He has been cited in Marquis Who's Who in America, in Medicine and Health Care, in Science and Engineering, and in the World.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
Lukic S.,Institute for Digestive Diseases |
Nikolic A.,Serbian Institute of Molecular Genetics and Genetic Engineering |
Alempijevic T.,Institute for Digestive Diseases |
Alempijevic T.,University of Belgrade |
And 11 more authors.
Digestive Surgery | Year: 2011
The purpose of this study was to determine the frequency of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and to investigate its role as a potential risk factor in patients with chronic pancreatitis and pancreatic cancer. Deletion polymorphism of the 287-bp fragment of intron 16 of the ACE gene results in higher levels of circulating enzyme and therefore may represent a risk factor for disease development. The study included 55 patients with chronic pancreatitis, 45 patients with pancreatic cancer and 128 healthy subjects. The presence of I and D variants in the ACE gene was analyzed by a polymerase chain reaction (PCR) method. Distribution of ACE ID genotypes was analyzed by means of logistic regression. When chronic pancreatitis and pancreatic cancer groups were compared in the univariate analysis, the following factors were identified as statistically significant predictors of pancreatic disease: age, gender, smoking, fat intake, ACE II genotype and ACE DD genotype. However, in the multivariate analysis, only age, gender and smoking were singled out as predictors for the occurrence of pancreatic disease. Our findings indicate that the ACE I/D polymorphism could play a role in the development of chronic pancreatitis and pancreatic cancer through interaction with other genetic and environmental factors. © 2011 S. Karger AG, Basel.
Cerovic I.,Institute for Digestive Diseases |
Mladenovic D.,University of Belgrade |
Jesic R.,Institute for Digestive Diseases |
Naumovic T.,University of Belgrade |
And 4 more authors.
European Journal of Gastroenterology and Hepatology | Year: 2013
Objective: The alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) (ANI) scoring system was constructed as a response to a clinical need for avoiding the risks of liver biopsy in diagnosing the etiology of fatty liver disease. The aim of this study was to test the reliability of ANI as a noninvasive method to distinguish ALD from NAFLD. Materials and Methods: One hundred and thirty-five patients were classified into two groups, ALD and NAFLD, according to the pathohistological results. Parameters for ANI are aspartate aminotransferase, alanine aminotransferase, mean corpuscular volume, BMI, and sex. ANI was calculated using an online calculator, official site of Mayo Clinic. Results: ANI was significantly higher in patients with ALD than NAFLD (P<0.01). The cutoff point of ANI is-0.66. ANI greater than-0.66 indicates ALD, whereas ANI less than-0.66 yields a higher probability of NAFLD with high specificity (96.7%) and sensitivity (84.1%). The mean corpuscular volume and aspartate aminotransferase/alanine aminotransferase ratio were higher, whereas BMI was lower in patients with ALD than in NAFLD (P<0.01). Conclusion: The ANI scoring system may be used for the estimation of alcoholic origin of steatosis/steatohepatitis and may help in triaging patients for liver biopsy. ANI less than-0.66 indicates NAFLD, whereas ANI greater than-0.66 confirms the alcoholic etiology, but does not exclude the contribution of associated factors toward the development of fatty liver in a Serbian population. © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Mladenovic D.,University of Belgrade |
Ninkovic M.,Military Medical Academy |
Vucevic D.,University of Belgrade |
Colic M.,Military Medical Academy |
And 4 more authors.
Journal of the Serbian Chemical Society | Year: 2013
The aim of this study was to investigate the effects of binge drinking on paracetamol-induced oxidative stress in mice liver. Male Swiss mice were divided into groups: control; ethanol-treated group (E) in five sequential doses of 2 g kg-1, administered through an orogastric tube; paracetamol-treated group (P) in a dose of 300 mg kg-1, intraperitoneally and a group that received paracetamol 12 h after the last dose of ethanol (PE). Blood and liver samples were collected for the determination of oxidative stress parameters 6, 24 and 48 h after treatment. Prior binge drinking potentiated the paracetamol-induced increase in the liver malondialdehyde level 48 h after treatment in comparison with the P and E groups (17.14±1.98 vs. 13.14±0.82 and 12.99±1.18 μmol L-1, respectively, p < 0.01). Ethanol and paracetamol in combination induced a more pronounced decrease in the liver GSH level than either of the individual substances alone at all time intervals (p < 0.01). Total liver superoxide dismutase (SOD) activity was significantly lower in PE 48 h after treatment in comparison with the P and E groups (251.73±80.63 vs. 707.62±179.92 and 1179.62±147.94 U mg-1 protein, respectively, p < 0.01). The lowest MnSOD activity in the PE group was detected 48 h after treatment (86.52±28.31; 41.13±11.07 and 23.16±5.18 U mg-1 protein in the P, E and PE groups, respectively, p < 0.05). Prior binge ethanol drinking potentiates paracetamolinduced reduction of antioxidative capacity of hepatocytes due to GSH depletion and SOD activity reduction, simultaneously increasing lipid peroxidation caused by paracetamol.
Radosavljevic T.,University of Belgrade |
Mladenovic D.,University of Belgrade |
Ninkovic M.,Military Medical Academy |
Vucevic D.,University of Belgrade |
And 5 more authors.
Journal of the Serbian Chemical Society | Year: 2012
The aim of this study was to investigate the effects of binge drinking on the prooxidant/antioxidant system in rat liver in acute cadmium (Cd) intoxication. Male Wistar rats were used in the experiments. They were divided into the following groups: 1. control, 2. ethanol-treated group, in five subsequent doses of 2 g kg -1, administered by an orogastric tube, 3. Cd-treated group in a single dose of 2.5 mg kg -1, administered intraperitoneally, 4. group that received Cd 12 h after the last dose of ethanol. Blood and liver samples for determination of oxidative stress parameters, were collected 24 h after treatment. When administered in combination, ethanol and Cd induced a more pronounced increase in the serum and liver malondialdehyde levels than either of the substances alone (p<0.01). Liver manganese superoxide dismutase (MnSOD) activity was increased in both the ethanol-and Cd-treated groups (p<0.01), while liver copper/zinc superoxide dismutase (Cu/ZnSOD) activity was elevated in the Cd group only. However, when administered in combination, ethanol and Cd induced a more pronounced decrease in liver MnSOD and Cu//ZnSOD activity 24 h after treatment (p<0.01). Based on our study, it can be concluded that ethanol may act synergistically with Cd in inducing lipid peroxidation and reduction in liver SOD activity. Copyright 2012 (CC) SCS.
Lebrec D.,French Institute of Health and Medical Research |
Bosch J.,Liver Unit Hospital IDIBAP and Ciberehd |
Jalan R.,University College London |
Dudley F.J.,Alfred Hospital and Baker Research Institute |
And 8 more authors.
European Journal of Clinical Pharmacology | Year: 2012
Purpose: To assess the effect of tezosentan, a parenteral dual ET receptor antagonist, on splanchnic and systemic hemodynamics in patients with cirrhosis. In addition, the safety, pharmacokinetics, and pharmacodynamics of tezosentan were evaluated. Methods: The population consisted of patients with cirrhosis with clinically significant portal hypertension. This was a randomized, double-blind, multicenter study. The patients were randomized 3:1 to tezosentan (3 mg/h for 2-3 h) or placebo. HVPG, hepatic blood flow (HBF, ICG method), and systemic arterial pressures were measured before and after tezosentan administration. Plasma concentrations of tezosentan and ET-1 were determined peripherally and in the hepatic vein. Results: Eighteen patients received tezosentan and six placebo. Baseline clinical, biochemical, and hemodynamic characteristics were balanced between the two groups. There was no significant treatment effect on HVPG. The extraction ratio (0.31), the plasma clearance of ICG (280 ml/min), and the HBF (1,430 ml/min) did not show any relevant changes during the infusion of tezosentan, and there were no differences between placebo- and tezosentan-treated patients. A linear relationship was observed between the maximum-fold increase in ET-1 concentration and the steady-state tezosentan plasma concentration (r=0.82). There was a strong correlation (r=0.88) between plasma clearance of ICG and that of tezosentan (10.2 l/h). Arterial pressure and heart rate did not significantly change in either group. Conclusion: In patients with cirrhosis, a 2-to 3-h tezosentan infusion was safe and well tolerated but did not change the HVPG. Tezosentan infusion had no influence on the extraction ratio and plasma clearance of ICG and did not change HBF. © Springer-Verlag 2011.
Colovic R.,Institute for Digestive Diseases |
Colovic N.,Institute of Haematology |
Grubor N.,Institute for Digestive Diseases |
Kaitovic M.,Institute for Digestive Diseases
Srpski Arhiv za Celokupno Lekarstvo | Year: 2010
Introduction: Although the third most common aneurysm within the abdomen, after aneurysms of the aorta and iliac arteries, splenic artery aneurysms are rare, but not exceptionally. Owing to new imaging techniques, they have been discovered with increasing frequency. Case Outline: Authors present a 47-year-old woman, multipara, who presented with left upper abdominal pain in whom X-ray showed a calcified ring in the area of distal pancreas. Selective angiography confirmed a splenic artery aneurysm of its proximal part. During an open surgery the aneurysm was excised (aneurismectomy) without immediate, early or late complications. The patient became symptom-free. Conclusion: In patients, particularly women, the multiparas who present with epigastric or left upper abdominal pain of unknown aetiology, splenic artery aneurysm has to be taken into account. Further diagnostic procedures such as plain X-ray and selective angiography in suspected cases should be performed. Surgery or other treatment modalities are to be seriously considered in all patients, particularly in those with increased risk of rupture.
Filipovic B.,Clinical and Hospital Center Bezanijska Kosa |
Kovcevic N.,Institute for Digestive Diseases |
Randjelovic T.,Clinical and Hospital Center Bezanijska Kosa |
Kostic S.,Clinical and Hospital Center Bezanijska Kosa |
Filipovic B.,Niko Niko
Hepato-Gastroenterology | Year: 2011
Background/Aims: Malnutrition appears to be a major and noticeable problem for hospitalized patients and often present in patients with gastrointestinal diseases. This study attempts to evaluate differences in nutritional status parameters and nutritional state differences among hospitalized patients with various gastrointestinal diseases and disorders. Methodology: Our study included 154 males and 146 females, aged 18-84 years old, with various gastrointestinal diseases and disorders. All patients underwent baseline nutritional assessment, including subjective global assessment (SGA), anthropometric measurements, bioelectrical impedance analysis (BIA), and biochemical markers. Results: Prevalence of malnutrition was 45.7%. The highest prevalence was detected among patients suffering from gastrointestinal malignancies and chronic pancreatitis. All parameters decreased with malnourishment levels, except CRP and in-hospital stay which rose with malnourishment grade. SGA and length of hospital stay negatively correlated with all analyzed variables of nutritional assessment, except CRP. Conclusions: Patients suffering from gastrointestinal malignancies, inflammatory bowel disease and peptic ulcer disease have more pronounced level of malnutrition. Body mass index, triceps skin fold thickness, mid-arm circumference, MAMC, wrist circumference, total protein level, albumin, cholesterol, glucose level, lymphocyte count, basal metabolic rate, body fat mass, fat free mass, muscle mass, total body water and resistance appeared to be inversely correlated with malnutrition. However, CRP level correlated positively with the malnutrition severity. SGA malnutrition level is dependant of hospitalization length. © H.G.E. Update Medical Publishing S.A.